Active transport of imatinib into and out of cells: implications for drug resistance.
about
Management of Chronic Myeloid Leukemia Patients Resistant to Tyrosine Kinase Inhibitors TreatmentPharmacogenetics of BCR/ABL Inhibitors in Chronic Myeloid LeukemiaThe role of reduced intracellular concentrations of active drugs in the lack of response to anticancer chemotherapyKinase-independent mechanisms of resistance of leukemia stem cells to tyrosine kinase inhibitorsRole of the plasma membrane transporter of organic cations OCT1 and its genetic variants in modern liver pharmacologyRole of solute carriers in response to anticancer drugsResistance to tyrosine kinase inhibition therapy for chronic myelogenous leukemia: a clinical perspective and emerging treatment optionsAbcg2 overexpression represents a novel mechanism for acquired resistance to the multi-kinase inhibitor Danusertib in BCR-ABL-positive cells in vitroIntracellular retention of ABL kinase inhibitors determines commitment to apoptosis in CML cellsTransport mechanisms and their pathology-induced regulation govern tyrosine kinase inhibitor delivery in rheumatoid arthritisA multi-system approach assessing the interaction of anticonvulsants with P-gpPTEN regulates BCRP/ABCG2 and the side population through the PI3K/Akt pathway in chronic myeloid leukemiaTyrosine kinase inhibitors in chronic myeloid leukaemia: which, when, for whom?A bead-based activity screen for small-molecule inhibitors of signal transduction in chronic myelogenous leukemia cells.Imatinib mesylate and nilotinib (AMN107) exhibit high-affinity interaction with ABCG2 on primitive hematopoietic stem cells.A study to explore the correlation of ABCB1, ABCG2, OCT1 genetic polymorphisms and trough level concentration with imatinib mesylate-induced thrombocytopenia in chronic myeloid leukemia patients.A gene expression signature of CD34+ cells to predict major cytogenetic response in chronic-phase chronic myeloid leukemia patients treated with imatinib.Small interfering RNA against BCR-ABL transcripts sensitize mutated T315I cells to nilotinibSelecting the best frontline treatment in chronic myeloid leukemiaMolecular mechanisms of acquired resistance to tyrosine kinase targeted therapyFirst report of phase 2 study of dasatinib with hyper-CVAD for the frontline treatment of patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia.Mechanisms of primary and secondary resistance to imatinib in chronic myeloid leukemia.Properties of CD34+ CML stem/progenitor cells that correlate with different clinical responses to imatinib mesylateDownregulation of organic cation transporters OCT1 (SLC22A1) and OCT3 (SLC22A3) in human hepatocellular carcinoma and their prognostic significance.Using functional genomics to overcome therapeutic resistance in hematological malignancies.The pharmacogenetics of imanitib.SLC22A1-ABCB1 haplotype profiles predict imatinib pharmacokinetics in Asian patients with chronic myeloid leukemia.Development and targeted use of nilotinib in chronic myeloid leukemia.Phase III study of nilotinib versus best supportive care with or without a TKI in patients with gastrointestinal stromal tumors resistant to or intolerant of imatinib and sunitinib.Interactions of tyrosine kinase inhibitors with organic cation transporters and multidrug and toxic compound extrusion proteinsMonitoring response and resistance to treatment in chronic myeloid leukemia.Tyrosine kinase inhibitors: Multi-targeted or single-targeted?The controversial role of the Hedgehog pathway in normal and malignant hematopoiesis.Oncogenic Kit signaling and therapeutic intervention in a mouse model of gastrointestinal stromal tumor.Synthesis and characterization of a BODIPY conjugate of the BCR-ABL kinase inhibitor Tasigna (nilotinib): evidence for transport of Tasigna and its fluorescent derivative by ABC drug transporters.ABC transporters in multi-drug resistance and ADME-Tox of small molecule tyrosine kinase inhibitors.Outcome of treatment of chronic myeloid leukemia with second-generation tyrosine kinase inhibitors after imatinib failureIn vivo imaging of Bcr-Abl overexpressing tumors with a radiolabeled imatinib analog as an imaging surrogate for imatinib.Interaction of innovative small molecule drugs used for cancer therapy with drug transporters.Selective Targeting to Glioma with Nucleic Acid Aptamers
P2860
Q26766299-CB3194E8-DBD4-4DDF-9FCC-69E5CA32B588Q26781539-0D7D9D3E-E7C3-4D96-948D-4AE0D33895ABQ26830005-1D912698-E84C-48F0-9CE5-6044DA708727Q26849792-EC7A74F8-78BD-4F62-964F-BBCBE5A44BBCQ27026858-B792AAFB-C7D9-4BDD-9468-7AF82B637EB4Q27027625-A0C2BEBE-738E-4833-9C8E-CA580FD6EAF0Q27028181-92DA3C64-CBC7-4BC6-ABFB-941BAF7B3291Q28477903-594AB703-2D9B-4FE3-A664-42EAD46E87F6Q28481327-F358D95E-1833-4DC2-B596-6A0B36225FE9Q28484465-995E8A2D-4EF6-417F-AFAD-BE1210FC281AQ28533527-61B2CA5E-0666-4D78-AB3E-FFE051FA5D49Q28540547-A76B0B2D-9A5A-4F62-B5FC-C21A71638C76Q30242015-BADBD3D0-0718-4086-B919-5531C794017FQ30981853-B5C6892F-9ED6-4B5C-BBAC-5C31098D824CQ33285468-5A76B199-2031-42CB-AD4A-0DDCDA7356D7Q33427392-E0B096BC-A108-4DF1-A379-C2C123F29314Q33597519-81F0D418-DAFE-463F-ABBB-D91E3B88401DQ33707394-36E71BFB-58A5-4F72-A84D-1ACAC3C4DCB4Q33764253-6D504581-9377-4071-A6EE-613081720A95Q33828409-8C1CD709-7607-458F-816F-D320FDDE7864Q33843477-D6076CFF-EAC5-4F79-881A-528AF8FBAF86Q34016866-61CA1256-DA4D-4855-87E3-A778111D687CQ34184723-E9422FF3-DF42-4D4D-8CFD-D19BC003BCD2Q34206748-D6538BEA-A80B-407D-B04B-93138B852509Q34401328-023B1522-3EEC-4072-ABEE-B25D27FECF12Q34469295-DD7F871C-3410-4666-9F5D-BC01252F93DDQ34525644-A12D9588-743A-4E8A-9089-8BE0E37FF184Q34613968-A203D699-FB5A-4C7C-BD04-F690C6EE34F5Q34636081-F328F73E-97C3-459E-A151-AB45751A7729Q34714353-0874ED40-C24A-4C58-8837-5F09D36EAEC5Q34761663-3FC7B894-E783-4BFD-82AE-867C16600739Q34983846-B851A6F0-4381-4EA7-B792-6BA9D05C59C7Q35026699-A6C6CD54-574B-4E66-9E38-B06B09B5F8B8Q35036482-033B03AF-3EC4-46D2-BE9E-BDAEA652F33AQ35141800-A9FCAF05-2F09-4D1A-A9C6-545CA91F3A91Q35171274-AC6AE563-7A37-492D-B093-F229430D3607Q35596200-1BA5FBCA-AF6B-4AE0-B96A-5F70B2C23528Q35600576-EBF6674E-75FD-4C93-9C0A-9F966E2F44F9Q35708124-B733C776-EF1A-48B1-B971-687D8921B917Q35740074-4FF2C70B-93D8-42A3-8892-5A6441FE282A
P2860
Active transport of imatinib into and out of cells: implications for drug resistance.
description
2004 nî lūn-bûn
@nan
2004 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
name
Active transport of imatinib into and out of cells: implications for drug resistance.
@ast
Active transport of imatinib into and out of cells: implications for drug resistance.
@en
Active transport of imatinib into and out of cells: implications for drug resistance.
@nl
type
label
Active transport of imatinib into and out of cells: implications for drug resistance.
@ast
Active transport of imatinib into and out of cells: implications for drug resistance.
@en
Active transport of imatinib into and out of cells: implications for drug resistance.
@nl
prefLabel
Active transport of imatinib into and out of cells: implications for drug resistance.
@ast
Active transport of imatinib into and out of cells: implications for drug resistance.
@en
Active transport of imatinib into and out of cells: implications for drug resistance.
@nl
P2093
P1433
P1476
Active transport of imatinib into and out of cells: implications for drug resistance.
@en
P2093
Julia Thomas
Lihui Wang
Richard E Clark
P304
P356
10.1182/BLOOD-2003-12-4276
P407
P577
2004-08-17T00:00:00Z